CCP 010

Drug Profile

CCP 010

Alternative Names: CCP-010

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Castle Creek Pharmaceuticals
  • Class Molecular chaperones
  • Mechanism of Action Enzyme modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tay-Sachs disease

Most Recent Events

  • 12 Oct 2017 Phase-II clinical trials in Tay-Sachs disease in USA before October 2017 (Castle Creek Pharmaceuticals pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top